Enzo Biochem (Enzo Biochem) Cash Flow from Financing : $-1.51 Mil (TTM As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jan. 2024, Enzo Biochem paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $0.02 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Enzo Biochem spent $0.02 Mil on financial activities for the three months ended in Jan. 2024.

Enzo Biochem Cash Flow from Financing Historical Data

The historical data trend for Enzo Biochem's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Cash Flow from Financing Chart

Enzo Biochem Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Cash Flow from Financing

Get a 7-Day Free Trial

4.19

7.00

-0.24

-1.13

Enzo Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash Flow from Financing	Get a 7-Day Free Trial															-0.06	3.27	-4.24	-0.52	-0.02

Enzo Biochem Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Enzo Biochem's Cash from Financing for the fiscal year that ended in Jul. 2023 is calculated as:

	Cash Flow from Financing		(A: Jul. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0.386	+	0	+	-1.136	+	0	+	0	+	-0.375
=	-1.13

Enzo Biochem's Cash from Financing for the quarter that ended in Jan. 2024 is:

	Cash Flow from Financing		(Q: Jan. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-0.022	+	0	+	0	+	0
=	-0.02

Cash Flow from Financing for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.51 Mil.

Enzo Biochem (NYSE:ENZ) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Enzo Biochem's issuance of stock for the three months ended in Jan. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Enzo Biochem's repurchase of stock for the three months ended in Jan. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Enzo Biochem's net issuance of debt for the three months ended in Jan. 2024 was $-0.02 Mil. Enzo Biochem spent $0.02 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Enzo Biochem's net issuance of preferred for the three months ended in Jan. 2024 was $0.00 Mil. Enzo Biochem paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Enzo Biochem's cash flow for dividends for the three months ended in Jan. 2024 was $0.00 Mil. Enzo Biochem received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Enzo Biochem's other financing for the three months ended in Jan. 2024 was $0.00 Mil. Enzo Biochem received $0.00 Mil on other financial activities.

Enzo Biochem Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (Enzo Biochem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Cash Flow from Financing

Comparable Companies

PRE DRIO PSNL AWH BIOQ MDXH OCX VNRX BIAF TTOO TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

EZB:Germany

Address

527 Madison Avenue, New York, NY, USA, 10022

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Executives

Steven J Pully	director	9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf	10 percent owner	105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian	officer: Chief Executive Officer	527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert	officer: Interim CFO	C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon	officer: Chief Operating Officer	527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff	director	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench	officer: CHIEF FINANCIAL OFFICER	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp	10 percent owner	HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri	director	455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv	10 percent owner	2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank	10 percent owner, other: See Remarks	ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203